DCT

3:26-cv-11157

Gilead Sciences Inc v. Zydus Lifesciences Global FZE

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-11157, D.N.J., 08/28/2026
  • Venue Allegations: Venue is alleged to be proper as to Defendant Zydus USA due to its incorporation and established place of business in New Jersey. Venue is alleged as to the foreign defendants, Zydus FZE and Zydus Ltd., on the basis that they may be sued in any judicial district where personal jurisdiction is established.
  • Core Dispute: Plaintiff alleges that Defendants' proposed generic versions of HIV/HBV antiviral drugs DESCOVY® and VEMLIDY® infringe eleven patents related to the active ingredient tenofovir alafenamide (TAF) and its various chemical forms, manufacturing processes, and pharmaceutical formulations.
  • Technical Context: The technology involves specific chemical forms and pharmaceutical formulations of tenofovir alafenamide (TAF), a key antiviral prodrug used in widely prescribed treatments for Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV).
  • Key Procedural History: This is a Hatch-Waxman action initiated by Plaintiff in response to Defendants' submission of two 505(b)(2) New Drug Applications (NDAs) seeking FDA approval to market generic versions of Plaintiff's DESCOVY® and VEMLIDY® products. The suit was filed within the 45-day statutory window following receipt of Defendants' Paragraph IV certification notice letters, triggering a potential 30-month stay on FDA approval of the generic products.

Case Timeline

Date Event
2010-01-01 Gilead begins developing TAF as a clinical candidate.
2011-08-16 Priority Date for '065 and '769 Patents
2011-10-07 Priority Date for '386, '534, '841, and '804 Patents
2014-03-04 U.S. Patent No. 8,664,386 Issues
2014-06-17 U.S. Patent No. 8,754,065 Issues
2015-05-12 U.S. Patent No. 9,029,534 Issues
2015-06-30 Priority Date for '338, '911, '323, and '408 Patents
2016-01-01 FDA approves DESCOVY® and VEMLIDY®
2016-03-29 U.S. Patent No. 9,296,769 Issues
2016-05-24 U.S. Patent No. 9,346,841 Issues
2016-06-13 Priority Date for '028 Patent
2017-06-13 U.S. Patent No. 9,676,804 Issues
2017-10-03 U.S. Patent No. 9,777,028 Issues
2026-05-19 U.S. Patent No. 12,629,338 Issues
2026-06-09 U.S. Patent No. 12,648,911 Issues
2026-06-23 U.S. Patent No. 12,661,323 Issues
2026-07-14 U.S. Patent No. 12,678,408 Issues
2026-07-16 Date of Zydus's F/TAF Notice Letter to Gilead
2026-07-29 Date of Zydus's TAF Notice Letter to Gilead
2026-08-28 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,754,065 - "Tenofovir Alafenamide Hemifumarate"

  • Patent Identification: U.S. Patent No. 8,754,065, "Tenofovir Alafenamide Hemifumarate," issued June 17, 2014 Compl. ¶55

The Invention Explained

  • Problem Addressed: The complaint states that the foundational antiviral compound, tenofovir, is potent but not viable as an oral medicine due to low bioavailability Compl. ¶44 This necessitated the creation of "prodrugs" that could be absorbed by the body and then convert to tenofovir Compl. ¶44 Even after developing the tenofovir alafenamide (TAF) prodrug, a new challenge arose: finding a commercially feasible form of TAF that was stable and suitable for pharmaceutical formulation Compl. ¶47 Compl. ¶49
  • The Patented Solution: The '065 Patent claims a specific salt form of TAF, tenofovir alafenamide hemifumarate, which the complaint describes as "a composition in which two molecules of TAF are associated with one molecule of fumaric acid" Compl. ¶48 This specific "TAF Hemi" form is identified as the actual drug substance used in Gilead's successful DESCOVY® and VEMLIDY® products, suggesting it solved the formulation and commercialization challenges Compl. ¶48 The patent's specification describes this form and its properties, including its crystalline structure characterized by X-ray powder diffraction (XRPD) U.S. Patent No. 8,754,065, col. 3:45-56
  • Technical Importance: The creation of this stable, commercially viable hemifumarate salt form enabled the widespread delivery of the highly effective TAF prodrug, which became a preferred treatment option for millions of people with HIV and HBV worldwide Compl. ¶51

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 1 of the '065 Patent Compl. ¶90
  • Independent Claim 1:
    • Tenofovir alafenamide hemifumarate.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent, but this is standard practice.

U.S. Patent No. 9,296,769 - "Tenofovir Alafenamide Hemifumarate"

  • Patent Identification: U.S. Patent No. 9,296,769, "Tenofovir Alafenamide Hemifumarate," issued March 29, 2016 Compl. ¶56

The Invention Explained

  • Problem Addressed: As with the '065 Patent, this patent addresses the need for a stable, orally bioavailable, and commercially feasible form of the TAF prodrug Compl. ¶44 Compl. ¶47 Compl. ¶49
  • The Patented Solution: The '769 Patent, like the related '065 Patent, claims the specific tenofovir alafenamide hemifumarate salt form Compl. ¶56 This salt form provided the necessary stability and properties for TAF to be successfully developed into the commercial drugs DESCOVY® and VEMLIDY® Compl. ¶48 The patent's specification details the synthesis and characteristics of this specific salt form U.S. Patent No. 9,296,769, col. 7:1-10:53
  • Technical Importance: As described for the '065 Patent, this invention was critical for translating the TAF prodrug into a successful and widely used therapeutic for HIV and HBV Compl. ¶51

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 1 of the '769 Patent Compl. ¶98
  • Independent Claim 1:
    • Tenofovir alafenamide hemifumarate.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

Multi-Patent Capsule: U.S. Patent No. 9,777,028

  • Patent Identification: U.S. Patent No. 9,777,028, "Co-Crystals, Salts and Solid Forms of Tenofovir Alafenamide," issued October 3, 2017 Compl. ¶57
  • Technology Synopsis: This patent relates to the invention of TAF sesquifumarate, another salt form of TAF Compl. ¶6 This work is part of the broader effort to find stable, commercially viable forms of the TAF prodrug Compl. ¶48
  • Asserted Claims: At least claim 7 is asserted Compl. ¶106
  • Accused Features: The complaint alleges that processes used to prepare TAF fumarates can produce TAF sesquifumarate, and that Zydus's products will therefore contain this form Compl. ¶84

Multi-Patent Capsule: TAF Process Patents

  • Patent Identification: U.S. Patent Nos. 8,664,386; 9,029,534; 9,346,841; and 9,676,804, titled "Methods for Preparing Anti-Viral Nucleotide Analogs," expiring in October 2032 Compl. ¶7
  • Technology Synopsis: These patents cover novel chemical methods to produce TAF in an efficient, reliable, and commercially feasible manner Compl. ¶7 These process inventions were developed to solve the problem that TAF is difficult to manufacture at commercially viable levels Compl. ¶45 Compl. ¶47
  • Asserted Claims: At least claim 1 of each of the Process Patents is asserted Compl. ¶114 Compl. ¶121 Compl. ¶128 Compl. ¶135
  • Accused Features: The complaint alleges that it is likely Zydus utilizes the claimed processes to manufacture its TAF-containing products Compl. ¶85

Multi-Patent Capsule: TAF Formulation Patents

  • Patent Identification: U.S. Patent Nos. 12,629,338; 12,648,911; 12,661,323; and 12,678,408, titled "Pharmaceutical Formulations Comprising Tenofovir Alafenamide and Emtricitabine," expiring in June 2036 Compl. ¶8
  • Technology Synopsis: These patents cover novel pharmaceutical formulations containing TAF and emtricitabine (FTC) Compl. ¶8 The problem addressed was formulating a stable combination tablet, as Gilead scientists discovered a relationship between the concentration of TAF and its stability in tablets also containing FTC Compl. ¶53
  • Asserted Claims: At least claim 1 of each of the Formulation Patents is asserted Compl. ¶142 Compl. ¶149 Compl. ¶157 Compl. ¶164
  • Accused Features: Zydus's F/TAF 505(b)(2) Product, an oral tablet containing both emtricitabine and tenofovir alafenamide, is accused of infringing these formulation patents Compl. ¶11 Compl. ¶71

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are two proposed generic drug products for which Defendant Zydus FZE has filed 505(b)(2) applications with the FDA Compl. ¶¶10-12:
    1. "Zydus's F/TAF 505(b)(2) Product": emtricitabine/tenofovir alafenamide oral tablets in a 200 mg/25 mg base strength, referencing Gilead's DESCOVY® Compl. ¶11
    2. "Zydus's TAF 505(b)(2) Product": tenofovir alafenamide oral tablets in a 25 mg base strength, referencing Gilead's VEMLIDY® (Compl. ¶12).

Functionality and Market Context

  • The accused products are intended as generic equivalents to Gilead's DESCOVY® and VEMLIDY® products, which are used for the treatment and prevention of HIV and for the treatment of chronic HBV Compl. ¶¶4-5 Compl. ¶¶86-87 The complaint alleges Zydus's applications represent that its products have the same dosage and are bioequivalent to Gilead's corresponding branded drugs Compl. ¶71 Compl. ¶76
  • The complaint alleges, upon information and belief, that Zydus's products contain a form of TAF fumarate, potentially including TAF monofumarate, TAF hemifumarate, and TAF sesquifumarate Compl. ¶80 Compl. ¶84 The complaint provides a 2D chemical structure of tenofovir alafenamide (TAF), illustrating its key components including the adenine base, the phosphonamidate linker, and the isopropyl ester group Compl. ¶45

IV. Analysis of Infringement Allegations

U.S. Patent No. 8,754,065 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
Tenofovir alafenamide hemifumarate. The complaint alleges, on information and belief, that the processes used to prepare TAF fumarates can also produce TAF hemifumarate, and that Defendants' accused products will therefore contain TAF hemifumarate. ¶84 col. 6:10-18

U.S. Patent No. 9,296,769 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
Tenofovir alafenamide hemifumarate. The complaint alleges, on information and belief, that because processes for making TAF fumarates can also yield TAF hemifumarate, Defendants' accused products will contain the claimed TAF hemifumarate composition. ¶84 col. 6:10-18

Identified Points of Contention

  • Scope Questions: The complaint indicates that Zydus, in its notice letters, contends its products do not infringe because they do not contain "tenofovir alafenamide hemifumarate" and alleges Gilead is "estopped from asserting that claim 1 encompasses tenofovir alafenamide monofumarate" Compl. ¶81 This raises the question of whether the claim term "tenofovir alafenamide hemifumarate" can be interpreted to cover a product that Zydus may argue is primarily TAF monofumarate, either literally or under the doctrine of equivalents. It also raises the question of whether Gilead disclaimed coverage of the monofumarate form during prosecution.
  • Technical Questions: A central evidentiary question is the exact chemical composition of Zydus's proposed products. The complaint acknowledges that discovery is required to "assess the exact composition of those products" Compl. ¶84 The infringement analysis will depend on whether Zydus's manufacturing process for its fumarate salt product results in the creation of the claimed hemifumarate salt, even as a byproduct or impurity.

V. Key Claim Terms for Construction

  • The Term: "Tenofovir alafenamide hemifumarate"
  • Context and Importance: This term constitutes the entirety of independent claim 1 of both the '065 and '769 patents. Its construction is dispositive for infringement of these claims. Zydus's non-infringement argument appears to center on a narrow definition of this term that distinguishes it from other fumarate salts, such as monofumarate Compl. ¶81 Practitioners may focus on this term because the dispute hinges on whether Zydus's product, which may be a different fumarate salt, nevertheless falls within the scope of this term, either literally (e.g., as part of a mixture) or under the doctrine of equivalents.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patents define the invention broadly as a hemifumarate form of TAF U.S. Patent No. 8,754,065, abstract A party might argue that the claim reads on any composition containing this 2:1 stoichiometric salt of TAF and fumaric acid, regardless of its purity or the presence of other salt forms.
    • Evidence for a Narrower Interpretation: The patents' detailed descriptions and examples characterize a specific crystalline solid with particular XRPD peaks and DSC thermograms U.S. Patent No. 8,754,065, col. 3:45-56 U.S. Patent No. 8,754,065, FIG. 1 A party might argue these specific, characterized properties define the claimed term, limiting its scope to substantially pure crystalline TAF hemifumarate and excluding its presence as a minor component in a mixture of other salts.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Defendants will induce infringement upon FDA approval of their 505(b)(2) applications Compl. ¶92 Compl. ¶100 The basis for inducement is the allegation that the proposed product labels will instruct and encourage physicians and patients to administer the products for infringing uses, namely the treatment of HIV/HBV (Compl. ¶86; Compl. ¶87). Knowledge is alleged based on Defendants' submission of applications referencing Gilead's drugs and patents, and receipt of Gilead's notice letters Compl. ¶92 Compl. ¶108
  • Willful Infringement: The complaint does not contain a specific count for willful infringement. However, it alleges that Defendants have knowledge of the patents-in-suit, a necessary predicate for willfulness, based on the Paragraph IV certifications and correspondence with Gilead Compl. ¶92 Compl. ¶108 The prayer for relief requests a finding that the case is "exceptional" under 35 U.S.C. § 285 Compl. ¶222(j)

VII. Analyst's Conclusion: Key Questions for the Case

  • A central factual question will be one of chemical composition: does Zydus's manufacturing process for its proposed TAF fumarate products result in the creation of detectable amounts of the claimed TAF hemifumarate salt, either as a primary component, a byproduct, or an impurity in a mixture? The case's trajectory will be heavily influenced by discovery on this point.
  • A core legal issue will be one of claim scope and estoppel: can the term "tenofovir alafenamide hemifumarate" be construed to cover a product that may be primarily a different salt form, and did Gilead disclaim coverage of other fumarate salts, such as TAF monofumarate, during prosecution, thereby limiting the scope of its claims under the doctrine of equivalents?